Shots:

• The company reported the preliminary efficacy & safety data from the P-III (VESPUCCI) trial to evaluate FYB202 vs Stelara in patients with mod. to sev. psoriasis vulgaris (PsO)
• The trial met the primary efficacy EPs, which showed a comparable efficacy b/w FYB202 & the reference Stelara, and no clinical differences in safety & immunogenicity were observed. The 1EPs of the study also measured the percent improvement of the PASI @12wks. from baseline
• Stelara has been used to treat multiple severe inflammatory conditions incl. mod. to sev. psoriasis & psoriatic arthritis. Additionally, Formycon had acquired 100% of the rights to FYB202 from ATHOS KG

Ref: FORMYCON | Image: FORMYCON